7/8/2005

A medical advisory panel in Canada recommended Merck's painkiller Vioxx be allowed back on the market despite some cardiovascular risk, and also said Pfizer's Celebrex should remain on the market. The panel recommended Pfizer's other arthritis drug, Bextra, also a Cox-2 inhibitor, be kept off the market, and said ibuprofen pain relievers, currently sold OTC, should be subject to restrictions. Health Canada must now decide whether to accept the panel's recommendations.

Related Summaries